Bluejay Diagnostics (BJDX) Stock Forecast, Price Target & Predictions
BJDX Stock Forecast
Bluejay Diagnostics stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BJDX Analyst Ratings
According to 1 Wall Street analysts, Bluejay Diagnostics's rating consensus is 'Buy'. The analyst rating breakdown for BJDX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 12, 2022 | Dawson James | - | Buy | Initialise |
Bluejay Diagnostics's last stock rating was published by Dawson James on Jan 12, 2022. The company Initialise its BJDX rating from "null" to "Buy".
Bluejay Diagnostics Financial Forecast
Bluejay Diagnostics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | $809.00K |
| High Forecast | - | - | - | - | - | - | $809.00K |
| Low Forecast | - | - | - | - | - | - | $809.00K |
| # Analysts | - | - | - | 1 | 1 | - | - |
| Surprise % | - | - | - | - | - | - | - |
Bluejay Diagnostics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BJDX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Bluejay Diagnostics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| EBITDA | - | - | - | - | $-2.33M | $-2.30M | $-2.68M |
| Avg Forecast | - | - | - | - | - | - | $485.40K |
| High Forecast | - | - | - | - | - | - | $485.40K |
| Low Forecast | - | - | - | - | - | - | $485.40K |
| Surprise % | - | - | - | - | - | - | -5.52% |
undefined analysts predict BJDX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bluejay Diagnostics's previous annual EBITDA (undefined) of $NaN.
Bluejay Diagnostics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| Net Income | - | - | - | - | $-2.30M | $-2.30M | $-2.24M |
| Avg Forecast | $-347.88K | $-347.88K | $-347.88K | $-13.59M | $-644.35K | $-898.92K | $-4.64M |
| High Forecast | $-347.88K | $-347.88K | $-347.88K | $-13.59M | $-483.26K | $-866.03K | $-4.64M |
| Low Forecast | $-347.88K | $-347.88K | $-347.88K | $-13.59M | $-805.44K | $-920.85K | $-4.64M |
| Surprise % | - | - | - | - | 3.57% | 2.56% | 0.48% |
Bluejay Diagnostics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BJDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Bluejay Diagnostics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| SG&A | - | - | - | - | $1.04M | $943.91K | $1.33M |
| Avg Forecast | - | - | - | - | - | - | $4.04M |
| High Forecast | - | - | - | - | - | - | $4.04M |
| Low Forecast | - | - | - | - | - | - | $4.04M |
| Surprise % | - | - | - | - | - | - | 0.33% |
Bluejay Diagnostics's average Quarter SG&A projection for Mar 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to BJDX last annual SG&A of $1.04M (Dec 23).
Bluejay Diagnostics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 1 | - | - |
| EPS | - | - | - | - | $-1.86 | $-2.08 | $-0.11 |
| Avg Forecast | $-0.72 | $-0.72 | $-0.72 | $-5.76 | $-0.52 | $-0.81 | $-9.60 |
| High Forecast | $-0.72 | $-0.72 | $-0.72 | $-5.76 | $-0.39 | $-0.79 | $-9.60 |
| Low Forecast | $-0.72 | $-0.72 | $-0.72 | $-5.76 | $-0.65 | $-0.83 | $-9.60 |
| Surprise % | - | - | - | - | 3.58% | 2.55% | 0.01% |
According to undefined Wall Street analysts, Bluejay Diagnostics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BJDX previous annual EPS of $NaN (undefined).
Bluejay Diagnostics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BJDX | Bluejay Diagnostics | $0.15 | $10.00 | 6566.67% | Buy |
| HSCS | Heart Test Laboratories | $3.04 | $3.00 | -1.32% | Buy |
BJDX Forecast FAQ
Is Bluejay Diagnostics a good buy?
Yes, according to 1 Wall Street analysts, Bluejay Diagnostics (BJDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of BJDX's total ratings.
What are Bluejay Diagnostics's analysts' financial forecasts?
Bluejay Diagnostics's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $809K (high $809K, low $809K), average EBITDA is $485.4K (high $485.4K, low $485.4K), average net income is $-6.182M (high $-5.988M, low $-6.365M), average SG&A $4.04M (high $4.04M, low $4.04M), and average EPS is $-10.935 (high $-10.775, low $-11.085). BJDX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-14.634M (high $-14.634M, low $-14.634M), average SG&A $0 (high $0, low $0), and average EPS is $-7.92 (high $-7.92, low $-7.92).